Hereditary angioedema plasma proteomics following specific plasma kallikrein inhibition with lanadelumab
Proteomic analyses of plasma from patients with HAE-C1INH before and after treatment with lanadelumab compared with healthy controls confirmed known HAE-C1INH biomarkers and identified additional potential biomarkers of plasma kallikrein dysregulation for further investigation.
Authors
- Anton Kichev
- Ezequiel Anokian (ORCID: https://orcid.org/0000-0003-0694-1867)
- Amanda MacDonald (ORCID: https://orcid.org/0000-0002-2356-7179)
- Salomé Juethner
- Bin Li
- Dan Sexton (ORCID: https://orcid.org/0000-0001-8224-1753)
- Dave Yeung
Institutions
- Clarivate (United States) (US)
- Takeda (United States) (US)
- Synta Pharmaceuticals (United States) (US)
- Takeda (Japan) (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fimmu.2024.1471168
- Citations
- 6
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 9.75
Funders
- Takeda Pharmaceuticals U.S.A.